Antonio Luca Maria Parlati
Overview
Explore the profile of Antonio Luca Maria Parlati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
28
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Parlati A, Madaudo C, Nuzzi V, Manca P, Gentile P, Di Lisi D, et al.
Card Fail Rev
. 2025 Feb;
11:e01.
PMID: 39981305
Congestion in patients with heart failure (HF) predicts adverse outcomes and is a leading cause of hospitalisation. Understanding congestion mechanisms helps in HF management and underscores the importance of tailored...
2.
Parlati A, Nardi E, Marzano F, Madaudo C, Di Santo M, Cotticelli C, et al.
J Clin Med
. 2025 Feb;
14(3).
PMID: 39941536
Cardiovascular magnetic resonance (CMR) imaging has become a cornerstone in the diagnosis, risk stratification, and management of cardiovascular disease (CVD), particularly heart failure (HF) and cardiomyopathies. Renowned as the gold...
3.
Parlati A, Nardi E, Basile C, Paolillo S, Marzano F, Chirico A, et al.
J Public Health Res
. 2024 Oct;
13(4):22799036241278817.
PMID: 39398345
Cardiovascular diseases (CVD) and mental health disorders (MHD) are respectively the first and second most prevalent diseases in high-income countries and the two most relevant causes of disability worldwide. The...
4.
Madaudo C, Parlati A, Di Lisi D, Carluccio R, Sucato V, Vadala G, et al.
J Cardiovasc Med (Hagerstown)
. 2024 Sep;
25(11):766-771.
PMID: 39347723
Artificial intelligence has increasingly become an integral part of our daily activities. ChatGPT, a natural language processing technology developed by OpenAI, is widely used in various industries, including healthcare. The...
5.
Madaudo C, Coppola G, Parlati A, Corrado E
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892201
This comprehensive review explores the various scenarios of atherosclerosis, a systemic and chronic arterial disease that underlies most cardiovascular disorders. Starting from an overview of its insidious development, often asymptomatic...
6.
Gargiulo P, Basile C, Galasso G, Bellino M, DElia D, Patti G, et al.
Eur J Prev Cardiol
. 2024 May;
31(15):1806-1816.
PMID: 38788773
Aims: No data are available on early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in patients with acute coronary syndrome (ACS) in the real world. This study investigates...
7.
Basile C, Parlati A, Paolillo S, Marzano F, Nardi E, Chirico A, et al.
Medicina (Kaunas)
. 2023 May;
59(5).
PMID: 37241180
: Depression is a common and severe comorbidity among individuals with heart failure (HF). Up to a third of all HF patients are depressed, and an even higher proportion have...
8.
Parlati A, Basile C, Perrone-Filardi P
Eur Heart J Suppl
. 2023 May;
25(Suppl C):C271-C275.
PMID: 37125281
Recommendations are the fundamental elements of guidelines and are especially significant when the amount of scientific data is expanding fast, as is the scenario of heart failure (HF). Beginning with...
9.
Basile C, Paolillo S, Gargiulo P, Marzano F, Asile G, Parlati A, et al.
J Cardiovasc Med (Hagerstown)
. 2022 Dec;
24(1):44-51.
PMID: 36574300
Background: The impact of sacubitril-valsartan on heart failure (HF) patients with preserved ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the clinical advantages and safety...
10.
Gargiulo P, Marzano F, Salvatore M, Basile C, Buonocore D, Parlati A, et al.
ESC Heart Fail
. 2022 Nov;
10(2):753-761.
PMID: 36349485
Heart failure is a leading cause of morbidity and mortality, with relevant social and economic burden on global healthcare system. Although the development of novel diagnostic tools and the advance...